Clopidogrel
What's New
Last Posted: Apr 02, 2022
- Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis
S Jiang et al, The PGX journal, April 1, 2022 - New genetic variants associated with major adverse cardiovascular events in patients with acute coronary syndromes and treated with clopidogrel and aspirin
X Liu et al, The Pharmacogenomics Journal, June 22, 2021 - Ischemic stroke and myocardial ischemia in clopidogrel users and the association with CYP2C19 loss-of-function homozygocity: a real-world study
N Gronich et al, The PGX journal, March 1, 2021 - The need of a multicomponent guiding approach to personalize clopidogrel treatment
C Valeria et al, Pharmacogenomics Journal, October 9, 2020 - Prediction Rule for Nonresponse to Clopidogrel: ABCD-GENE Score
ACC, March 3, 2020 - Clopidogrel Pharmacogenetics - Why the Wait?
Roden Dan M et al. The New England journal of medicine 2019 10 (17) 1677-1678 - Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases
Ye Zhu, et al. Genetics in Medicine, October 8, 2019 - Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting.
Martin Jesse et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Jul - P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes.
Povsic Thomas J et al. JAMA cardiology 2019 May - Association Between ABCB1 Polymorphisms and Outcomes of Clopidogrel Treatment in Patients With Minor Stroke or Transient Ischemic Attack- Secondary Analysis of a Randomized Clinical Trial
Y Pan et al, JAMA Neurology, February 11, 2019 - One Step Closer to Precision Medicine Strategies Based on Genetic Information-ABCB1 Polymorphisms in the CHANCE Trial-
BP George et al, JAMA Neurology, February 11, 2019 - Local Coverage Determination (LCD): Biomarkers Overview (L35062)
The U.S. Centers for Medicare & Medicaid Services - CLINGEN Actionability Report for Cerebral cavernous malformations 1, 2, and 3 - KRIT1, CCM2, PDCD10
ClinGen Actionability Working Group - Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine.
Rakicevic Ljiljana et al. Clinical pharmacology and therapeutics 2018 Jun - Clinical Relevant Polymorphisms Affecting Clopidogrel Pharmacokinetics and Pharmacodynamics: Insights from the Puerto Rico Newborn Screening Program.
Hernandez-Suarez Dagmar F et al. International journal of environmental research and public health 2018 May 15(6) - CYP2C19 or CYP3A5 Genotyping Does Not Predict Clinical Response to Clopidogrel.
Rodríguez-González Fayna et al. Journal of clinical pharmacology 2018 May - Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Cavallari Larisa H et al. Journal of translational medicine 2018 Apr 16(1) 92 - Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).
Bergmeijer Thomas O et al. American heart journal 2018 Apr 198152-159 - Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Zeb Irfan et al. Expert review of cardiovascular therapy 2018 Apr 1-9 - CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment.
Hou Xumin et al. Journal of clinical laboratory analysis 2018 Feb
More
About RCH PHGKB
Reproductive and Child Health PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to reproductive and child Health...more
Content Summary
Common RCH Related Topics
- Attention Deficit/Hyperactivity Disorder
- Autism
- Birth Defects
- Carrier Testing
- Cerebral Palsy
- Congenital heart defects
- Pregnancy loss
- Developmental Disabilities
- Gestational Diabetes
- Hearing loss
- Neural tube defects
- Infant Mortality
- Infertility
- Learning disability
- Newborn Screening
- Preeclampsia
- Prematurity
- Prenatal Testing
- Stillbirth
- Sudden Infant Death Syndrome
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Page last updated:May 03, 2024
- Content source: